secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001193125-25-025663
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant assembles outside expert panel to review bexotegrast trial after DSMB pause recommendation
--------------------------------------------------------------------------------

- DSMB recommended pause of enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast in IPF.
- Company initiated assembly of outside expert panel (pulmonary experts and biostatisticians) to review unblinded data.
- Company could not determine DSMB rationale from blinded data; panel will provide independent recommendation then join expanded DSMB.
- Process expected to conclude in 2-4 weeks; company remains blinded to maintain trial's potential as registrational.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312525025663/0001193125-25-025663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312525025663/d892128d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-025663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer